|
Updated August 2009 by Charles Gomersall
- Meta-analysis suggests that prophylaxis with fluconzale decreases risk
of invasive candidiasis and prophylaxis with fluconazole or ketoconazole
reduces mortality. Problem is that this data gives no guidance regarding
which patients should receive prophylaxis
- expert opinion is that antifungal prophylaxis may be warranted in ICUs
with very high rates of invasive candidiasis (compared with "normal" rates
of 1-2% of patients). This should be given to patients with the highest
(>10%) risk of invasive candidiasis
Further reading
Pappas PG. Guidelines for treatment of candidiasis:
2009 update by Infectious Diseases Society of Ameria. Clin
Infect Dis 2009; 48:503-535
Potential conflict of interest
The Dept of Anaesthesia & Intensive Care, Chinese
University of Hong Kong has received educational grants and payment for research
from Pfizer Corporation Hong Kong Ltd and educational grants from Merck Sharp
& Dohme. Dr Gomersall has received a speaker's
honorarium from Pfizer Corporation | 
